The tiny German biotech needs strong signals to emerge from an approaching read out of its chemokine-targeting lead project.
Gelesis’s weight-loss capsule only hit one of the two co-primary endpoints in its approval trial. Will the FDA be persuaded?
Technology developed by GTX Medical has shown astonishing results in paralysed patients. Monetising it might be an even more impressive achievement.
The world’s first non-implanted vagus nerve stimulator is becoming established as a therapy for headache and migraine. But a move into autoimmune conditions will require…
Forming partnerships with a number of players in diabetes technology is the key to growth, according to Ascensia Diabetes Care.
The UK company Midatech Pharma is giving up on speciality drugs to focus on cancer and rare diseases – and it has Novartis in its sights.
Voxeleron is, like Google’s related company Deepmind, using artificial intelligence to analyse ocular images. Unlike Deepmind, it is employing a targeted approach.
The company’s plan to cut jobs and look at external deals could be a sign that it is becoming more like other big pharmas.
Encouraging early data in inflammatory bowel disease have given Abivax a second avenue to pursue with its lead HIV asset.